A research team led by scientists from the Cancer Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) has developed a novel peptide drug called FFW that could potentially stop the development of hepatocellular carcinoma (HCC), or primary liver cancer. This landmark discovery opens the door for more effective treatment of liver cancer with...
Tag: <span>Cancer Drug</span>
Post
FDA grants first approval for CA drug under new pilot programs
(HealthDay)—The U.S. Food and Drug Administration has approved Ribociclib (Kisqali) in combination with an aromatase inhibitor (AI) as an initial endocrine-based therapy for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. Ribociclib has also been approved with fulvestrant as initial...
Post
X-rays burst chemo-filled nanobubbles for targeted cancer drug delivery
Researchers at the Center for Nanoscale BioPhotonics (CNBP) have developed a new targeted treatment for cancer. Chemotherapy drugs are wrapped in “nano-bubbles” called liposomes, which are then injected into the desired part of the body and made to release their payload on demand, by applying X-ray radiation. A new potential cancer treatment uses nanobubbles called...
Post
Research team discovers drug compound that stops cancer cells from spreading
Fighting cancer means killing cancer cells. However, oncologists know that it’s also important to halt the movement of cancer cells before they spread throughout the body. New research, published today in the journal Nature Communications, shows that it may be possible to freeze cancer cells and kill them where they stand. Ryan Gordon, Ph.D., and Raymond Bergan,...
Post
Genetic material once considered junk actually could hold key to cancer drug response
A hairpin loop from a pre-mRNA. Highlighted are the nucleobases (green) and the ribose-phosphate backbone (blue). Note that this is a single strand of RNA that folds back upon itself. Material left out of common processes for sequencing genetic material in cancer tumors may actually carry important information about why only some people respond to immunotherapy,...
Post
New drug attacks cancer-causing genes
Two recent papers attack two cancer-related problems using the same drug. They hope that it might improve survival in breast and lung cancer and halt obesity-related cancers. Research gives a deeper insight into the molecular changes associated with cancer. Researchers from Michigan State University in East Lansing are using novel molecular routes to attack cancer. The...
Post
Pediatric cancer drug shows 93 percent response rate
Briana Ayala, left, with her oncologist, Dr. Ted Laetsch. Dr. Laetsch had Briana’s tumor tested for a TRK fusion and then successfully treated her with larotrectinib. Credit: UT Southwestern Medical Center A first-of-its-kind drug targeting a fused gene found in many types of cancer was effective in 93 percent of pediatric patients tested, researchers at...
Post
Discovery of unsuspected flexibility offers new pathway to cancer drug development
Summary of novel cross-family VEGF and PDGF ligand-receptor interactions. Schematic illustrates an updated view of the VEGF and PDGF ligand-receptor binding patterns, adding newly discovered PDGF-VEGFR interactions. Specifically, only new …more Blood vessels are the supply lines of the human body, bringing nutrients and oxygen to cells and carrying away waste. Controlling the growth of...
Post
Layered Microparticles Carry Cancer Drug, Can be Imaged and Activated Using Ultrasound
At the University of Alabama at Birmingham, scientists have developed a new microparticle that carries doxorubicin chemo load, that can be imaged within the body and then made to release the cargo using external ultrasound. The polymer particles consist of layers of tannic acid and poly(N-vinylpyrrolidone), or TA/PVPON, both fairly biocompatible substances. They are generated over a...
Post
Newfound Effect of Cancer Drug May Expand its Use
NEW YORK, Feb. 10, 2017 /PRNewswire-USNewswire/ — A drug first designed to prevent cancer cells from multiplying has a second effect: it switches immune cells that turn down the body’s attack on tumors back into the kind that amplify it. This is the finding of a study led by researchers from NYU Langone Medical Center and published recently in Cancer Immunology...